Study shows benefits, drawbacks, for women's incontinence treatments

October 4, 2012

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

After six months, in both treatment groups said that the average number of daily episodes had declined from about five per day to about 1-2 per day.

In the study, the researchers compared the effectiveness of to oral anticholinergic medications for treating urge in women. Nearly 250 women participated in the trial comparing Botox injections with anticholinergic medications. On average, the women were 58 years old. Anticholinergic medications reduce bladder contractions by targeting the bladder muscle through the nervous system. Many women who take anticholinergic medications relate having unpleasant side effects, including constipation, dry mouth and

The proportion of women receiving Botox whose urinary leakage completely went away six months after starting treatment (27 percent) was twice that of the group taking (13 percent). Women in the Botox group were more likely to experience incomplete bladder emptying or bladder infections, while the women taking the medication were a little more likely to report that they had dry mouth— a common side effect of the medication.

The study focused on treatment for urge urinary incontinence— the unpredictable release of urine shortly after feeling the urge to urinate. Information on urge incontinence as well as other kinds of incontinence is available from the National Institute of Diabetes, Digestive, and Kidney Diseases at http://kidney.niddk.nih.gov/kudiseases/pubs/uiwomen/index.aspx.

Women are twice as likely as men to experience urinary incontinence, and are more likely to experience it than are . An estimated 15.7 percent of U.S. women experience urinary incontinence. Pregnancy and childbirth, menopause, and the structure of the female urinary tract account for this difference.

"This is the first study to compare the effectiveness of Botox treatments to oral medication," said study senior author Susan F. Meikle, M.D., M.S.P.H., of the Contraception and Reproductive Health Branch of the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Program Director of the Pelvic Floor Disorders Network (PFDN). "Previously, Botox was reserved for women who had tried oral medications but found them ineffective. Because we included some women who had not been treated with oral medication before, these results suggest that Botox could be discussed as an option for first line treatment."

First author Anthony G. Visco, M.D., of Duke University Medical Center, in Durham, N.C., was the principal investigator of the study. He collaborated with Dr. Meikle and researchers affiliated with Loyola University Chicago; University of Alabama at Birmingham; University of Utah, Salt Lake City; Cleveland Clinic; Kaiser Permanente San Diego; University of Texas Southwestern Medical Center in Dallas; University of Pittsburgh; Oakwood Hospital and Medical Center, Dearborn, Mich.; Oakland University, Royal Oak, Mich.; University of Michigan, Ann Arbor; RTI International, Research Triangle Park, N.C.; and other researchers associated with the NICHD-supported PFDN.

In addition to the NICHD, the NIH Office of Research on Women's Health supported the study.

The findings appear online in the New England Journal of Medicine.

Urge incontinence results from unpredictable activity of the bladder muscles, the cause of which is often unknown. Botox injections work by relaxing the overactive muscles. In August 2011, the U.S. Food and Drug Administration approved Botox, or onabotulinumtoxinA, for the treatment of urge urinary incontinence when the cause of the overactive bladder is known, and due to spinal cord injury, multiple sclerosis or other disorders.

OnabotulinumtoxinA is not FDA-approved to treat an overactive bladder without a neurologic cause, even when other therapies have been found to be ineffective.

Women diagnosed with urge urinary incontinence were divided randomly into two groups. One received Botox injections in the bladder muscle and also for six months received placebo (sugar) pills. The other group received a saline injection in the and took oral anticholinergic medication for six months. The study participants— as well as their doctors or other staff— did not know whether the women had received anticholinergics or Botox.

Each month, the women recorded the number of leakage episodes they experienced over a three-day period. They also answered questionnaires about their symptoms and quality of life.

About 90 percent of the women in each group responded to treatment within one month. At the end of six months, about 70 percent of the women in each group reported that their symptoms were adequately controlled.

All women were instructed to stop taking the pills after six months, but the researchers continued to monitor the effectiveness of both treatments for an additional six months. Nine months after the start of their treatment, 52 percent of the women who had received Botox reported adequate symptom control, compared with 32 percent in the oral anticholinergic drug group. At 12 months, the figures were 38 percent and 25 percent.

In addition, side effects in the two groups differed. Two months after the start of treatment, women in the group needed to use a catheter more often to empty their bladders completely (5 percent vs. 0) and were more likely to experience urinary tract infections (33 percent vs. 13 percent). Women taking the oral anticholinergic medication were more likely to report (46 percent vs. 31 percent).

According to Dr. Visco, ongoing studies seek to evaluate the cost-effectiveness of the two approaches.

Explore further: US approves Botox for bladder control

Related Stories

US approves Botox for bladder control

August 24, 2011
The face-freezing pharmaceutical injection Botox gained another medical use on Wednesday when the US government approved it for use in some patients with overactive bladder.

Botox now used for urinary incontinence

March 14, 2012
When you think of Botox injections, you probably think of getting rid of unwanted wrinkles around the eyes or forehead, but recently the U.S. Food and Drug Administration (FDA) approved using the injections to help patients ...

Invasive bladder testing before incontinence surgery may be unnecessary

May 2, 2012
Invasive and costly tests commonly performed on women before surgery for stress urinary incontinence (SUI) may not be necessary, according to researchers at the University of California San Diego, School of Medicine and the ...

Powerful treatment provides effective relief for urinary incontinence

March 12, 2012
The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect ...

Recommended for you

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.